Premium
Targeting of Nanotherapeutics to Infection Sites for Antimicrobial Therapy
Author(s) -
Dong Xinyue,
Zhang Can Yang,
Gao Jin,
Wang Zhenjia
Publication year - 2019
Publication title -
advanced therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.125
0ISSN - 2366-3987
DOI - 10.1002/adtp.201900095
Subject(s) - antimicrobial , antibiotics , immune system , nanomedicine , infectious disease (medical specialty) , pathogen , anti infective agents , microbiology and biotechnology , biology , immunology , medicine , disease , nanotechnology , materials science , pathology , nanoparticle
Bacterial infections cause a wide range of host immune disorders, resulting in local and systemic tissue damage. Antibiotics are pharmacological interventions for treating bacterial infections, but increased antimicrobial resistance and the delayed development of new antibiotics have led to a major global health threat, the so‐called “superbugs.” Bacterial infections consist of two processes: pathogen invasion and host immune responses. Developing nanotherapeutics to target these two pathways may be effective for eliminating bacteria and restoring host homeostasis, thus possibly finding new treatments for bacterial infections. This review offers new approaches for developing nanotherapeutics based on the pathogenesis of infectious diseases. The mechanisms through which nanoparticles target infectious microenvironments are outlined, alongside a discussion of techniques that used target phagocytes to deliver antibiotics to eliminate intracellular pathogens. A new concept is also reviewed—host‐directed therapy for bacterial infections, such as targeting immune cells for the delivery of anti‐inflammatory agents and vaccine developments using bacterial‐membrane‐derived nanovesicles. This review demonstrates the translational potential of nanomedicine for improving infectious disease treatments.